Corona Remedies Ltd is a domestic pharmaceutical company focused on prescription-based branded generics across acute and chronic therapies. Its revenue comes primarily from manufacturing and marketing formulations in cardiovascular, diabetes, gastro, pain management, and dermatology segments. Its products are used by healthcare providers for treating common and lifestyle-related diseases.


The Company is led by Promoter, i.e., MR. KARAN NARANG, MR. VISHAL NARANG, MS. NAMITA NARANG , MR. AYUSH JAIN & MR. YASH JAIN

The Revenues from operations for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 3,485.59 Million, ₹ 12,023.53 Million, â‚¹ 10,209.31 Million, and ₹ 8,911.01 Million, The EBITDA for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were â‚¹ 717.96 Million, ₹ 2,459.13 Million, ₹1,611.90 Million, and ₹ 1,350.30 Million, The Profit after Tax for the Period ended on June 30 2025, and Fiscals ended on Mar 31, 2025, 2024 and 2023 were were â‚¹ 461.96 Million, ₹ 1,494.34 Million, â‚¹ 905.03 Million, and ₹ 849.29 Million, respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of â‚¹24.43 and post-issue EPS of ₹24.43 for FY25. The pre-issue P/E ratio is 43.47x,while the post-issue P/E ratio is 43.47x against the Industry P/E ratio is 43.74x The company's ROE for FY25 is 27.50% and RoNW is 24.65% The Annualised EPS is ₹30.21x and P/E is 35.15x. These metrics suggest that the IPO is Fairly priced.

The Grey Market Premium (GMP) of Corona Remedies showing listing gains of 16.80%.Given the company's financial performance and the valuation of the IPO, we recommend  Investors to Apply to the Corona Remedies Limited IPO for Listing gain or Long Term Purposes.